Carolyn F. Deacon
Associate Professor
- Published
Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.
Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.
Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes
Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170Research output: Contribution to journal › Journal article › Research › peer-review
- Published
What do we know about the secretion and degradation of incretin hormones?
Deacon, Carolyn F., 2005, In: Regulatory Peptides. 128, 2, p. 117-24 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
MK-431 (Merck).
Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Immunoassays for the incretin hormones GIP and GLP-1
Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 9220
Most downloads
-
390
downloads
Glucagon-like peptide-1 receptor signaling in acinar cells causes growth dependent release of pancreatic enzymes
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
308
downloads
Acute effects of dietary carbohydrate restriction on glycemia, lipemia and appetite regulating hormones in normal-weight to obese subjects
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
302
downloads
Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
Research output: Contribution to journal › Journal article › Research › peer-review
Published